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CUTANEOUS PHARMACOLOGY OF THE TETRACYCLINES*
STANLEY I. CULLEN, MI.t AND ROBERT G. CROUNSE, MD4
The tetracycline antibiotics are widely pre-
scribed in present dermatologic practice. They
are employed in the treatment of infectious
diseases of the skin such as impetigo, ecthyma,
various pyodermas, granuloma inguinale and
syphilis. They are also used in certain other dis-
eases such as dyshidrotic hand eruptions and
acne vulgaris, in which their mode of action is
either uncertain or unknown. Studies of the
systemic pharmacology and toxicology of these
drugs are numerous but our knowledge of their
cutaneous pharmacology is extremely limited.
Increased concentrations of tetracydines may
be found in cutaneous and internal malignant
tumors (1, 2), necrotic tissue (2, 3), abscesses
(4), bones (5) and teeth (6). The studies of
Kelly et al. (7) using radioisotopically labeled
demethyl-chiortetracycline in dogs, Gould and
Ritchie (8) measuring the oxytetracycline con-
tent of human skin and Welch (9) measuring the
distribution of oxytetracycline and chiortetra-
cycine in rabbits, are the only publications
found in which the concentration of a tetra-
cycline in various normal tissues, including skin,
has been quantitated.
The problem of establishing adequate skin
levels of antibiotic for the successful treatment
of a given cutaneous infection has been neglected.
The equivocal response of acne vulgaris to oral
tetracycline therapy demonstrates this problem
(10). Are apparent failures based upon inade-
quate gastrointestinal absorption and inade-
quate skin levels of antibiotic? The tetracyclines
are known to be absorbed erratically, with some
foods and drugs markedly diminishing its ab-
sorption (11).
Similarly, the complete explanation for the
high incidence of photosensitivity reactions in
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patients receiving demethylchlortetracycline, in
contrast to the negligible incidence following in-
gestion of other chemically related tetracyclines
is not clear. Although demethyichiortetracycine
is a slightly more potent photosensitizer (12),
do other factors such as skin levels, differences
in metabolic degradation rates, or other un-
known factors play a role?
Investigation of these problems required the
utilization of a sensitive method for the assay
of these antibiotics in normal and abnormal
human skin. This report details the results of
such experiments.
METhOD AND MATERIALS
Skin and serum tetracycline and demethylchior-
tetracycline were determined by the spectropho-
tofluorometric method of Kohn (13). The assay
is based on the formation of ethyl acetate ex-
tractable complexes of tetracycline with calcium
and barbiturate. These complexes have character-
istic fluorescent spectra. Kohn's procedure III was
followed with certain modifications for use with
serum and skin. Fluorescence intensities were
measured by means of an Aminco-Bowman spec-
trophotofluorometer. All fluorescence spectra were
recorded by use of an Electro X-Y recorder. To be
certain of the purity of the tetracycline complex
being measured, all specimens were scanned with
respect to excitation and emission spectra, using
both the Electro X-Y recorder and the cathode
ray oscillosope. On our spectrophotofluorometer
the peak excitation wave length for tetracycline is
395 m and the peak emission wave length is 520
me. For demethylchiortetracycline the peak ex-
citation wave length is 400 m and the peak emis-
sion wave length is 530 m.
Accurate and reproducible results could be ob-
tained by the addition of 0.5 ml of serum to 4.5
ml of 0.1 M HCl and then extraction by shaking
at 5°C. for one hour. The skin sample was ob-
tained by a four or six millimeter punch biopsy,
wet weight 8 to 45 milligrams after blotting. The
tissue was cut into small pieces, mixed in a test
tube containing a small amount of broken glass
and 5 ml of 0.1 M HC1 and shaken at 5°C. for
one hour with a Vortex tube shaker. The addition
of small pieces of broken glass provided more
complete homogenization of skin tissue than was
possible by other methods.
All glassware was washed sequentially with 95
per cent ethyl alcohol, chromic acid, 1 per cent
ethanol and acetone, and subsequently examined
for interfering fluorescent substances. This pro-
cedure was found to be absolutely essential to
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preclude contamination. Avoidance of stopcock
grease and redistillation of reagent grade ethyl
acetate were necessary.
Standard solutions were prepared as outlined by
Kohn (13). The unknown quantity of tetracycline
in a specimen was determined by comparison with
freshly prepared standard solutions. The fluores-
cence is proportional to the concentration be-
tween 0.01 micrograms per milliliter and 0.5 micro-
grams per milliliter solutions. Concentrations in
excess of 0.5 micrograms per milliliter and not
linearly related to fluorescence and levels below
0.01 micrograms per milliliter cannot be accurately
determined. Specimens with concentrations of
tetracycline greater than 0.5 micrograms per milli-
liter in the final phase of the assay were diluted
so that readings fell into the most accurate range.
Quantities as low as 0.003 micrograms per speci-
men could be detected, but not quantitated.
Known quantities of tetracycline added to skin
and serum, then allowed to stand at room tem-
perature for one hour, were processed in the usual
manner. Repeated experiments of this nature
demonstrated a recovery of from 95 to 110 per
cent of the added compound.
All systemic or topical medications except the
tetracycline under investigation were withheld
during the period of investigation. The control
group included 39 normal volunteers. Eleven
subjects with psoriasis constitute one of the ex-
perimental groups. Nine of these patients have
clinically typical and microscopically confirmed
psoriasis. The second experimental group was
made up of 19 patients with various types of non-
psoriatic dermatitis.
RSBTJLT5
The simultaneous serum and skin levels of
tetracycline and demethyichiortetracycline as
determined on 39 normal subjects are tabulated
in Table I. Twenty-seven received tetracycline
and 12, demethylchlortetracycline. The period
of drug administration ranged from a single dose
to as long as six weeks. Serum levels are pri-
marily dependent on the length of time since the
last dose of antibiotic, which accounts for the
variation seen. In no case was tetracycline or
demethyl-chlortetracycline detected in normal
skin, even in the presence of circulating anti-
biotic. The fact that no antibiotic was detected
in the normal skin does not necessarily indicate
total absence, but rather less than 0.003 micro-
grams per specimen, which is the lower limit of
detectability of this test.
Assay of tetracycline (Table II) and de-
methylchlortetracycline (Table III) in involved
and uninvolved areas of the skin of patients with
various types of dermatitis confirmed the ab-
sence of antibiotic in the normal skin. Significant
amounts of each of these antibiotics were found
in all areas of dermatitis. The trichioracetic acid
dermatitis was induced in volunteers by painting
them with 50 per cent trichioracetic acid, allow-
ing it to remain on the skin for 60 seconds and
then wiping the area with alcohol to remove ex-
cess acid.
Eleven patients with psoriasis were studied
(Table IV). Of these 11 patients, nine had clin-
ically typical and microscopically confirmed pso-
riasis. The remaining patients (A.O. and W.D.)
had clinically suggestive and microscopically
compatible psoriasis. One patient (M.L.) had
erythema of the apparently normal skin from
natural sunlight at the time of the biopsy. De-
tectable amounts of the antibiotic found in the
apparently normal skin of these patients were
TABLE I
Skin and serum levels of tetracyclines—normal sub5ecs
Drug Dose Subjects Serum (jig/mi) atTime of Biopsy
Skin (jsg/gm wet weight)
Before Drug After Drug
Tetracycline 1101 2 gm, single dose
250 mg, q.i.d. X 7
250 mg, q.i.d.X 14
2
22
1
6.0 and 9.5
0.4 to 7.0
1.6
None detected*
None detected
250 mg, q.i.d. X 30
250mg,q.i.d.X42
1
1
5.4
3.9 (Not done)
Demethylchlortetra-
cycline 1101
150 mg, q.i.d. X 7
150mg, q.i.d. X 14
10
2
1.2 to 6.1
2.1 and 3.3 None detected
* Lower limits of detectability—0.003 fig.
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TABLE II
,Skin and serum levels of tefracycline—non-psoriatic dermatitis
Pt. Drug
Serum (pg/mi)
at Time of
Biopsy
Diagnosis
Skin (jig/gm wet weight)
Uninvolved Involved
S.B.
A.B.
E.T.
E.W.
F.W.
E.G.
W.Z.
E.S.
L.H.
W.J.
P.R.
500 mg, q.i.d. 5 da.
250 mg, q.i.d. 7 da.
250 mg, q.i.d. 7 da.
250 mg, q.i.d. 7 da.
250 mg, q.i.d. 7 da.
250 mg, q.i.d. 7 da.
250 mg, q.i.d. 7 da.
250 mg, q.i.d. 7 da.
250 mg, q.i.d. 7 da.
250 mg, q.i.d. 7 da.
250 mg, q.i.d. 7 da.
8.0
4.3
2.8
4.2
6.1
5.3
0.7
4.4
7.0
4.4
3.8
Atopic dermatitis
Psoriasiform dermatitis
Psoriasiform dermatitis
Psoriasiform dermatitis
Mycosis fungoides
Pityriasis rubra pilaris
Keratosis follicularis
Contact dermatitis
Trichioracetic acid der-
matitis
Trichioracetic acid der-
matitis
Trichloracetic acid der-
matitis
None detected*
None detected
None detected
None detected
None detected
None detected
None detected
None detected
None detected
None detected
None detected
4.8
3.5
26.5
11.9
8.1
12.2
16.7
24.7
18.6
19.2
14.5
* Lower limits of detectability—0.003 pg.
TABLE III
Skin and serum levels of demethylchlortetracyeline—izon-psoriatic dermatitis
Pt. Drug
Serum (pg/mi)
at Time of
Biopsy
Diagnosis
Skin (jig/gm wet weight)
Uninvolved Involved
S.S.
M.P.
J.C.
E.C.
N.C.
H.S.
E.C.
N.C.
150 mg, q.i.d. 7 days
150 mg, q.i.d. 7 days
150 mg, q.i.d. 7 days
150 mg, q.i.d. 7 days
150 mg, q.i.d. 7 days
150 mg, q.i.d. 7 days
l5Omg,q.i.d.lOdays
150mg, q.i.d. 10 days
3.6
2.9
2.2
5.6
6.1
2.6
2.8
1.1
Nummular eczema and
furuncles
Eczematous dermatitis
Squamous cell carcinoma
Trichloracetic acid der-
matitis
Trichloracetic acid der-
matitis
Trichloracetic acid der-
matitis
Sunburn
Sunburn
None detected*
None detected
None detected
None detected
None detected
None detected
None detected
None detected
Skin 8.0
Pustule 4.4
5.7
3.3
4.6
11.6
21.7
16.0
15.4
* Lower limits of detectability—0.003 pg.
only slightly less than the amounts found in the
clinical lesion. In one patient (J.S.) the amount
of tetracycline in a specimen of dermis from
which the epidermis had been scraped off was
7.1 micrograms of tetracycline per gram wet
weight of tissue. A whole specimen (dermis plus
epidermis) obtained at the same time contained
8.8 micrograms per gram of wet weight of tissue,
indicating that the bulk of the measurable tetra-
cycline was contained in the dermis.
Psoriatics taking tetracycline exhibit diffuse
yellow fluorescence when examined under Wood's
light. It was found, however, that the presence
and estimated degree of fluorescence varied with
different observers and, therefore, was of little
practical value.
DISCUSSION
The measurement of a substance which is
present in both skin and blood requires evidence
that the values obtained truly represent skin
levels, rather than simply reflecting contamina-
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TABLE IV
Skin and serum levels of tetracyclines—psoriasis
Pt. Drug
Serum
(/zn1)t
Skin (pg/gm
wet weight)
Biopsy Unin- In-
volved volved
M.L. TO, 250
q.i.d. 3 da.
mg, 4.4 8.1 32.7
A.O. TC, 250
q.i.d. 7 da.
mg, 2.8 4.5 10.5
D.I. TC, 250
q.i.d. 7 da.
mg, 5.1 5.9 7.1
P.M. TO, 250
q.i.d. 7 da.
mg, 8.9 8.0 9.5
J.B. TO, 250
q.i.d. 7 da.
mg, 3.1 4.5 9.4
M.S. TC, 250
q.i.d. 7 da.
mg, 2.9 5.7 11.9
W.D. TO, 250
q.i.d. 7 da.
mg, 3.8 6.1 10.2
J.S. TO, 250
q.i.d. 7 da.
mg, 3.5 8.8 8.4
S.F. DMOT, 150
q.i.d. 7 da.
mg, 6.1 7.0 8.2
Z.H. DMCT, 150
q.i.d. 7 da.
mg, 2.2 11.3 14.8
tion of the specimen with blood containing the
substance being measured. Accordingly, partic-
ular care was taken to obtain a skin specimen
which was free of obvious contamination with
blood. The biopsy site was heavily infiltrated
with 1 per cent Xylocaine®, it having been pre-
viously demonstrated that neither Xylocaine'
nor epinephrine interferes with the assay for
tetracycline. Biopsies were done rapidly with
special attention given to removal of the speci-
men prior to its contamination with blood from
the cut edges of the biopsy site.
The distribution of tetracycline in the cells and
noncellular components of whole human blood is
not completely known. There is some evidence
(7) that the antibiotic is equally distributed be-
tween red blood cells and plasma. In one patient
(W.Z.) red blood cell tetracycline level was
determined along with the plasma level. This was
found to be 0.88 micrograms per milliliter of red
blood cells. Calculations based on serum level
of drug at time of biopsy, concentration of anti-
biotic in the specimen, and total wet weight of
the specimen reveal in each instance that
trapped blood could not account for the findings
reported. If tetracyclines are homogeneously
distributed in whole blood, it would require a
quantity of whole blood ranging from a low of
75 per cent of the total weight of the specimen
to a high of 400 per cent of the total weight of
the specimen to account for the findings. If most
of the tetracycline is in the plasma, then it would
take an amount of blood from 1.5 to 8 times
the total weight of the specimen to account for
the results. The values for normal control skin
(Table I) and the normal skin of patients with
dermatitis (Table II) further indicate that sig-
nificant amounts of blood do not contaminate
the specimens, since no antibiotic was detected
in these specimens even in the presence of sig-
nificant amounts of circulating antibiotic.
The finding that we were unable to detect
tetracycline in normal skin is of particular inter-
est when compared to those studies (7, 8, 9) that
did.
Kelley, et al. (7) utilizing doses of 10 mgm/
Kg of 140-labelled demethylchlortetracycline in
two dogs found high concentrations of radio-
activity in all tissues except the subcutaneous
fat. Welch (9), using a bioassay, studied the
distribution of oxytetracycline and chlortetra-
cycline in rabbits. He stated that "concentration
of terramycin in the skin was several times that
of the blood concentration". Unfortunately the
exact concentrations are not stated. The extra-
polation of comparative animal studies to man
are not always valid.
The study by Gould and Ritchie (8) is the only
publication in which the concentration of a tetra-
cycline in normal human skin has been deter-
mined. They analyzed large quantities of skin
for oxytetracycline in 12 patients undergoing a
plastic surgical procedure. They report levels of
oxytetracycline ranging from 1.75 micrograms
to 4.0 micrograms per milliliter of skin suspen-
sion. It is not possible from the data presented
to know what this means in terms of micrograms
per gram of skin. It is possible that by using
larger quantities of skin, they were able to de-
tect lower concentrations with their bioassay
than we were able to detect with small pieces of
skin with the fluorometric assay. Points of in-
terest and importance not discussed in their
paper are the possibilities that the antibacterial
effect was not due to the tetracycline, but due
to other antibacterial substances either occurring
naturally in the skin or added subsequently in
the pre-surgical preparation. Another possibility
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is that the trauma induced by the pre-surgical
preparation of the skin was sufficient to increase
the oxytetracycline concentration in this tissue.
The absence of tetracycline in the skin of
normal controls and in the normal skin of pa-
tients with dermatitis, and their presence in
areas of dermatitis concurs with those studies
(1—5) that demonstrate concentration of tetra-
cycline in rapidly growing, necrotic or inflamed
tissues.
Vassar et al. (2) studied tetracycline fluores-
cence in several types of carcinomas and in be-
nign skin ulcers. The gross fluorescence was
confined to the tumor area and to the ulcers in
all cases. Fluorescent microscopy demonstrated
tetracycline in the macrophages and tissue debris
of the tumor stroma, but not in the malignant
cells. This localization of the tetracycline in the
inflammatory cells and tissue debris may relate
to our demonstration of tetracycline in areas of
dermatitis and not in normal skin. Mustakallio
(3) has presented photographic evidence of the
presence of tetracycline in palmar pustules and
in a squamous cell carcinoma. He postulates that
calcium chelate of tetracycline precipitates in
the presence of certain lipoproteins and sulfated
mucopolysaccharides.
The finding that apparently normal skin of
patients with psoriasis contains tetracycines in
contrast to the normal skin of patients with var-
ious dermatitides tested is another example of a
metabolic abnormality in the apparently normal
skin of psoriatics; several studies have demon-
strated such abnormalities (15—17). Thus it is
probable that the psoriatic process, whatever
the etiology or metabolic defect may be, be-
speaks a generalized cutaneous involvement.
No correlation between the tetracycline levels
of uninvolved skin of psoriatics and the clinical
activity of the psoriasis (actively spreading or
quiescent) could be determined.
These studies demonstrate that tetracyclines
do reach inflamed skin in concentrations ade-
quate to combat susceptible cutaneous infec-
tions. Spittel et al. (18) confirmed the presence
of antibiotics in ischemic tissue and Lock et al.
(4) found them in the granuloma pouch of rats.
Both of these studies demonstrated that the
antibiotic which is concentrated in areas of in-
flammation has biologic activity.
The present investigations provide a quanti-
tative method for determining the amounts of
tetracycline in abnormal cutaneous states. This
approach provides for the potential solution of
many problems in human cutaneous pharmacol-
ogy of tetracycline.
SITh4MARY
Successful quantitation of tetracydines in skin
following oral administration of these antibiotics
in therapeutic doses has been achieved. Neither
tetracycline nor demethylchlortetracydine was
detected in significant amounts in normal skin,
even in the presence of considerable amounts of
the antibiotic in the serum. Significant amounts
of these antibiotics were found, however, in areas
of dermatitis, even when none was detectable
in adjacent normal skin. The apparently unin-
volved skin of subjects with psoriasis, as well
as the psoriatic lesions themselves, contained
significant amounts of antibiotic, further evi-
dence that the uninvolved skin of psoriatics is
not normal.
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